Epidermal growth factor (EGF)

Modality

Epidermal growth factor (EGF) is a 53-amino-acid cytokine proteolytically cleaved from a large integral membrane protein precursor. And it was the first growth factor to be discovered.

Recombinant epidermal growth factors have been extensively studied and developed as cancer vaccines (CimaVax EGF, regEFP-p64K/Mont) and as skin injury/wound healing therapeutics (e.g., Heberprot-P, Regen-D 150, Easyef).

Application of EGF

Recombinant EGF for Wound Healing/Skin Lesions

The mechanism of action of epidermal growth factors is connected with increased proliferation of keratinocytes and higher tensile strength of newborn skin. Current EGF-based therapies include topical, cutaneous, and intralesional injections.

Recombinant human epidermal growth factor has been used in the treatment of diabetic foot ulcers (Heberprot-P, Regen-D 150, Easyef), vascular ulcers and bed sores (Regen-D 150), burns and site donor skin grafts (Regen-D 60).

EGF as Cancer Therapeutical Vaccines (CimaVax EGF)

The EGF-PTI vaccine based on the epidermal growth factor has been approved in Cuba for use in patients with stage IIIB/IV non-small cell lung cancer (NSCLC) after front-line CTP. As the first-in-class therapeutic vaccine for lung cancer, CimaVax-EGF consists of recombinant human EGF manufactured in yeast, and it is chemically linked to the recombinant P64K protein derived from Neisseria meningitides and produced in Escherichia coli. The EGF-PTI vaccine is adjuvanted with an aluminium hydroxide or Contained ISA51. It is developed by CIMAB. Bioven has been granted exclusive rights to CimaVax-EGF in the United States and Biotech Pharmaceuticals in China.

Yaohai Bio-Pharma Offers One-Stop CDMO Solution for EGF

Epidermal growth factor (EGF) Pipelines

Generic Name	Brand Name/ Alternative Name	Expression System	Indications	Manufacturer	R&D Stage
Nepidamine	Beta-urogastrone, Easyef, Urogastrone, DWP-401	Escherichia coli (E. coli)	Diabetic Foot Ulcer, Oral Mucositis,Dry Eye Syndrome	Daewoong Pharmaceutical Co., Ltd.	Approved
Topical recombinant human epidermal growth factor	Kanghesu(康合素)	E. coli	ulcers, burns, wounds	Haohai Biological Technology Co., Ltd.	Approved
Recombinant human epidermal growth factor derivative eye drops	GeneSoft, rEGF derivative, Kim In-soo	E. coli	Dry eye disease, corneal disease, burns	Shenzhen Watsin Genetech Co., Ltd., Uni-Bio Science Group	Approved
Recombinant human epidermal growth factor topical solution	GeneTime, rEGF, Kim In-tai	E. coli	Dry eye disease, corneal disease, burns	Shenzhen Watsin Genetech Co., Ltd., Uni-Bio Science Group	Approved
PX-070101	Pending update	Pending update	diabetic foo	Praxis Pharmaceutical	Approved
Recombinant epidermal growth factor	Heberprot-P, hrecEGF, Heberprot-P 75	Pending update	burns, diabetic foot	Elea Spa	Approved
Epidermal growth factor	Pending update	Pending update		bioMérieux SA	Approved
Recombinant epidermal growth factor	hrecEGF, REGEN-D 150, REGEN-D 60, REGEN-D 10	Pending update	burns, diabetic foot	Bharat Biotech International Limited	Approved
Recombinant human epidermal growth factor	yifu(易孚)	Yeast	burns, skin ulcers	Guilin Warnover Gene Pharmaceutical Co., Ltd.	Approved
Recombinant human epidermal growth factor eye drops	yibei(易贝)	Yeast	corneal disease, dry eye	Guilin Warnover Gene Pharmaceutical Co., Ltd.	Approved
Lyophilized mouse epidermal growth factor	yifu(一夫)	Pending update	Trauma and Injury	Hangzhou Tianmu Beidou Bio Pharmaceutical Co. Ltd.	Approved
Human epidermal growth factor (EGF) conjugate vaccine	CIMAv, CimaVax EGF, EGF vaccine (rEGF-p64K/Mont vaccine), chemical conjugate vaccine	E. coli and Yeast	Non-small cell lung cancer	Constellations Pharmaceuticals, BIOTECH PHARMACEUTICAL CO., LTD	Approved
IN-03,recombinant protein	tumor therapeutic vaccines	Pending update	tumors	In3Bio	Phase II
IN-04	Pending update	Pending update	tumors	In3Bio	Phase I
TTI-1612	oral recombinant protein	Pending update	Interstitial Cystitis/Bladder Pain Syndrome	Trillium(Acquired by Pfizer)	Phase I
MP-0274 fusion protein	CME-114, CME-119, CME-118, CME-115, DARPin-41, SPA-28, MP 0274	Pending update	tumors, solid tumors	Molecular Partners AG	Phase I
ZZ-06	recombinant Ganoderma lucidum immunomodulatory protein 70Lys	Pending update	EGFR-positive advanced solid tumors	Changchun Intellicrown Pharmaceutical Co., Ltd	Phase I

Reference:

[1] Decoster L, Wauters I, Vansteenkiste JF. Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. Ann Oncol. 2012 Jun;23(6):1387-93. doi: 10.1093/annonc/mdr564.

All Categories

Epidermal growth factor (EGF)

Modality